Ion Beam Applications SA

Brussels Stock Exchange IBAB.BR

Ion Beam Applications SA Free Cash Flow for the year ending December 31, 2023: USD -35.41 M

Ion Beam Applications SA Free Cash Flow is USD -35.41 M for the year ending December 31, 2023, a -343.93% change year over year. Free cash flow is the amount of cash a company generates after accounting for cash outflows to support operations and maintain its capital assets.
  • Ion Beam Applications SA Free Cash Flow for the year ending December 31, 2022 was USD 14.52 M, a -84.06% change year over year.
  • Ion Beam Applications SA Free Cash Flow for the year ending December 31, 2021 was USD 91.05 M, a -20.92% change year over year.
  • Ion Beam Applications SA Free Cash Flow for the year ending December 31, 2020 was USD 115.14 M, a 151.65% change year over year.
  • Ion Beam Applications SA Free Cash Flow for the year ending December 31, 2019 was USD 45.75 M, a 209.39% change year over year.
Key data
Date Free Cash Flow Operating Cash Flow Net Cash Used For Investing Activities Net Cash Used Provided By Financing Activities
Market news
Loading...
Brussels Stock Exchange: IBAB.BR

Ion Beam Applications SA

CEO Mr. Olivier Legrain
IPO Date Jan. 4, 2000
Location Belgium
Headquarters 3, Chemin du Cyclotron
Employees 1,943
Sector Health Care
Industries
Description

Ion Beam Applications SA develops, manufactures, and supports medical devices and software solutions for cancer treatments in Belgium, the United States, and internationally. The company operates through Proton Therapy and Other Accelerators, and Dosimetry segments. The Proton Therapy and Other Accelerators segment develops, fabricates, and services medical and industrial particle accelerators, and proton therapy systems. This segment also offers turnkey solutions for the treatment of cancer through the use of proton beams; and a line of cyclotrons used for the production of positron emission tomography or SPECT radioisotopes, as well as a line of industrial accelerators for sterilization and ionization. The Dosimetry segment provides solutions and services that enhances efficiency and minimizes errors in radiation therapy and medical imaging quality assurance and calibration procedures. The company has strategic research and development partnership with SCK CEN (Belgian nuclear research center) to enable the production of Actinimum-225 (225Ac), a novel radioisotope for the treatment of cancer; and an agreement with University of Pennsylvania for advance research in ConformalFLASH. Ion Beam Applications SA was incorporated in 1986 and is headquartered in Louvain-la-Neuve, Belgium.

Similar companies

BEKB.BR

NV Bekaert SA

USD 33.74

-0.13%

EVS.BR

EVS Broadcast Equipment SA

USD 31.12

0.60%

MELE.BR

Melexis NV

USD 60.03

0.18%

BAR.BR

Barco NV

USD 9.69

0.18%

StockViz Staff

January 15, 2025

Any question? Send us an email